pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$CMPSCOMPASS Pathways plc

$CMPS8.1200+1.75%
Chesire, GBupdated 2h ago

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA).

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
7
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
psilocybin
Treatment Resistant Depression
5-hydroxytryptamine receptor 2A

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 3, 2026
earnings
$CMPS8.1200+1.75%
16d ago
COMPASS Pathways plc earnings
COMPASS Pathways plc
→
view all catalysts →

Active trials

  • phase3A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)active not recruitingn=168
🐶 Hiring Signal
No open roles indexed yet — view COMPASS Pathways plc jobs →

News

  • Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
    Helus Pharma's psilocin-based HLP003 significantly reduced symptoms of major depressive disorder in the adjuvant setting in a Phase 3 trial but was tripped up in the stock market by three serious a…
    biospace · 2d ago
  • Helus' chemically modified psychedelic hits key goals in phase 3 depression trial
    Helus Pharma's oral chemically modified version of psilocybin hit the key goals of a phase 3 study as an adjunctive treatment in major depressive disorder.
    fiercebiotech · 3d ago
  • HHS pumps up to $25M into ibogaine, other psychotropic drugs on Veteran’s Day
    Ibogaine, which operates via a “matrix pharmacology,” has long been a focus of Health Secretary Robert F. Kennedy Jr. and the Trump administration.
    biospace · 5d ago
  • FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
    In advance of a Senate vote on Heidi Overton as the next FDA commissioner, the agency has shelved the Commissioner's National Priority Voucher program introduced by former leader Marty Makary, Reut…
    biospace · 6d ago
  • ARPA-H bets $4.9 million on ibogaine for PTSD treatment in veterans
    The U.S. department of health and human services announced a $4.9 million bet to advance the development of ibogaine for post-traumatic stress disorder (PTSD).
    fiercebiotech · 6d ago
  • AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
    The deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
    biopharma_dive · 7d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 8d ago
  • Delix raises $100M to advance at-home psychedelic without hallucinatory effects
    The series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.
    biospace · 8d ago
  • Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumbles
    Plus, news about Immunovant, Abeona Therapeutics, Ellodi Pharmaceuticals, Spruce Biosciences, Adrenyx Biosciences, Edesa Biotech, Kyorin Pharmaceutical, Charles River Laboratories, Frontage, Compas…
    endpoints · 9d ago
  • Update: Compass submits psilocybin depression drug for approval after stock wobbles
    Compass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…
    biospace · 9d ago
view all news mentions →
identifiers
ticker
$CMPS
SEC CIK
0001816590
country
GB
source
sec_tickers
top tags
Cardiology1Major Depression1Obesity1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?